Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

Cited by (759)

Items 501–600 of 759

1. Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma
   F. Ingegnoli, A. Tourlaki, R. Gualtierotti · 2014 · Clinical drug investigation
2. Rheumatoid Arthritis Disease Progression Modeling
   R. Reeve, Lei Pang, Bradley Ferguson, M. O’Kelly, Seth Berry, Wei Xiao · 2013 · Therapeutic Innovation and Regulatory Science
3. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
   T. Herlin · 2012 · Expert Review of Clinical Immunology
4. Immune modulation of rheumatoid arthritis.
   D. Pappas, L. Geraldino-Pardilla, J. Bathon · 2011 · Baillière's Best Practice & Research : Clinical Rheumatology
5. Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
   S. Mori, Y. Ueki · 2011 · Modern Rheumatology
6. Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.
   B. Bizzini, B. Drouet, D. Zagury, M. Abitbol, A. Burny, M. Boissier · 2010 · Immunotherapy
7. Biologic Agents for Rheumatoid Arthritis: 2008 and Beyond
   N. Sweiss, Linda L Hushaw · 2009 · Journal of Infusion Nursing
8. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
   Brandon M. Johnson, Lihong Cheng, Jennifer D. Koenitzer, Ian M. Catlett, Peter H Schafer · 2024 · Frontiers in Immunology
9. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study
   A. Zubrzycka-Sienkiewicz, K. Klama, M. Ullmann, C. Petit-Frère, Peter Baker, J. Monnet, A. Illes · 2024 · RMD Open
10. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
    X. Leng, Piotr Leszczyński, S. Jeka, Sheng-Yun Liu, Hua-Xiang Liu, M. Miakisz, Jie-Ruo Gu, L. Kilasonia, M. Stanislavchuk, Xiaolei Yang et al. · 2024 · The Lancet Rheumatology
11. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials
    Young Ho Lee, Gwan Gyu Song · 2023 · Zeitschrift für Rheumatologie
12. Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid Arthritis Patients Treated With Methotrexate Versus Tocilizumab: 24-week Results From a Prospective Randomized Controlled Study
    J. Yeo, H. Baek, Y. Song, E. Y. Lee · 2022 · Journal of Rheumatic Diseases
13. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis.
    C. Specker, A. Alberding, M. Aringer, G. Burmester, J. Flacke, M. W. Hofmann, P. Kästner, H. Kellner, F. Moosig, M. Sieburg et al. · 2020 · Clinical and Experimental Rheumatology
14. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice
    V. Bykerk, A. Östör, J. Álvaro-Gracia, K. Pavelka, J. R. Román Ivorra, M. Nurmohamed, Yves Luder, P. Sidiropoulos, J. Devenport, J. Sibilia · 2019 · Clinical Rheumatology
15. Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis
    Emma L. Simpson, Shijie Ren, Emma Everson-Hock, John Stevens, Aymeric Binard, Yves‐Marie Pers, Rachel J. Archer, Suzy Paisley, Matthew D. Stevenson, Chloé Herpin et al. · 2019 · International Journal of Technology Assessment in Health Care
16. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018
    F. Bartoli, S. Bae, L. Cometi, Marco Matucci Cerinic, D. Furst · 2018 · Expert Review of Clinical Immunology
17. New therapeutic approaches in rheumatoid arthritis.
    R. van Vollenhoven · 2016 · Presse medicale
18. Ulcérations buccales aphtoïdes persistantes associées au tocilizumab : deux cas
    M. Samimi, F. Lauferon, B. Huttenberger, L. Vaillant, P. Goupille, L. Machet · 2013
19. Tocilizumab for the treatment of rheumatoid arthritis
    J. Rueda-Gotor, M. González-Gay, R. Blanco · 2012
20. Use of biological therapies in rheumatoid arthritis management: a comparison between the main worldwide and brazilian recommendations.
    V. Fernandes, Tássia Moraes de Assis, C. C. Queiroz, Patrícia Pires Rey de Figueiredo, Rafaela Untar de Oliveira, N. D. da Silva · 2011
21. Considerations about the 2011 consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis.
    Licia Maria Henrique da Mota · 2011 · Revista Brasileira de Reumatologia
22. Rationale of using different biological therapies in rheumatoid arthritis
    M. Geyer, U. Müller-Ladner · 2010 · Arthritis Research & Therapy
23. Tocilizumab
    Dennis J. Cada, T. Levien, D. Baker · 2010
24. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’?
    Robert J. Moots, Andrew J.K. Östör, John Dudley Isaacs · 2009 · Expert Opinion on Investigational Drugs
25. Newer Biological Agents in the Treatment of Rheumatoid Arthritis
    M. Nurmohamed · 2009 · Drugs
26. RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists
    E. Choy · 2009 · Nature Clinical Practice Rheumatology
27. Codon Optimization, Cloning and Expression of the Human Leukemia Inhibitory Factor (hLIF) in E. coli
    Parichehr Darabi, H. Galehdari, S. Khatami, N. Shahbazian, M. Shafeei, A. Jalali, A. Khodadadi · 2012 · Iranian Journal of Biotechnology
28. Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
    Meng-Duan Pang, Zhe Sun, Hong-Feng Zhang · 2022 · Medicine
29. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
    E. Choy, R. Caporali, R. Xavier, B. Fautrel, R. Sanmartí, M. Bao, J. Devenport, A. Pethö-Schramm · 2019 · Rheumatology
30. Endothelial lipase is upregulated by interleukin-6 partly via the p38 MAPK and p65 NF-κB signaling pathways
    Xin Yue, Ming-Hui Wu, Hong Jiang, J. Hao, Qinghao Zhao, Qing Zhu, G. Saren, Yun Zhang, Xiao-Li Zhang · 2016 · Molecular Medicine Reports
31. Herpes Zoster Meningitis Complicating Combined Tocilizumab and Cyclosporine Therapy for Adult-Onset Still's Disease
    Shinichiro Tsurukawa, Nozomi Iwanaga, Yasumori Izumi, Atsunori Shirakawa, Chieko Kawahara, T. Shukuwa, Miwako Inamoto, A. Kawakami, K. Migita · 2016 · Case Reports in Rheumatology
32. Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious
    H. Lindegaard, P. Johansen, G. Gröndal, E. Jensen, L. Juul, A. Schlemmer, B. Agular, I. Hansen · 2016 · Scandinavian Journal of Rheumatology
33. Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East
    M. Hammoudeh, Adel Al Awadhi, E. Hasan, M. Akhlaghi, A. Ahmadzadeh, B. Sadeghi-Abdollahi · 2015 · International Journal of Rheumatology
34. Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system
    Anke Salmen, Ralf Gold, Andrew Chan · 2013 · Clinical & Experimental Immunology
35. Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
    S. Yılmaz, I. Simsek · 2013 · Therapeutics and Clinical Risk Management
36. Unmet Needs in the Treatment of Rheumatoid Arthritis
    Janet Elizabeth Pope, Bernard G Combe · 2013 · Open Journal of Rheumatology and Autoimmune Diseases
37. Synthesis and characterization of Bi2S3@NH2-MIL125(Ti) and survey the sono-catalytic ozonation process’s efficiency in the degradation of tocilizumab from aqueous
    J. Mehralipour, Bayan Vakili, E. Aria, Majid Kermani, Nahid Ghobadi · 2024 · Inorganic Chemistry Communications
38. Real-world retention rates of biologics in patients with rheumatoid arthritis
    Kenji Takami, S. Tsuji · 2023 · Scientific Reports
39. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
    J. Tesser, A. Gül, E. Olech, K. Oelke, T. Lukić, K. Kwok, Abbas Ebrahim · 2023 · Arthritis Research & Therapy
40. The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysis
    A. Mokbel, M. Movahedi, E. Philippopoulos, Pantea Ojani, E. Keystone · 2023 · Journal of clinical rheumatology
41. Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis
    J. Best, Y. Kuang, Yi-Lin Jiang, Rajpal Singh, A. Karabis, J. Uyei, J. Dang, W. Reiss · 2020 · Rheumatology and Therapy
42. Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
    P. Hilliquin, T. Barnetche, A. Baillet, R. Flipo, E. Lespessailles, C. Roux, P. Fardellone, Anika Gilbert-Marceau, I. Idier, A. Constantin et al. · 2020 · Rheumatology and Therapy
43. Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
    J. Best, S. Vlad, J. Pei · 2020 · Rheumatology and Therapy
44. Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial
    L. Bazzichi, F. Nacci, L. Sinigaglia, L. Bianchino, R. Caporali · 2018 · Clinical Rheumatology
45. Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis
    Eva‐Maria Didden, Yann Ruffieux, Noemi Hummel, Orestis Efthimiou, Stephan Reichenbach, Sandro Gsteiger, Axel Finckh, Christine Fletcher, Georgia Salanti, Matthias Egger · 2018 · Medical Decision Making
46. Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome
    Chuanyin Sun, Yingwan Luo, Hongyan Tong, Guanhua Xu, Jin Lin · 2018 · Medicine
47. Anatomic-Functional (Perfusion-Based) Magnetic Resonance Imaging Follow-up in Patients With Rheumatoid Arthritis Treated With Anti–Interleukin 6 Antibodies: A Comparison With Clinical Scores and Serologic Data
    U. Grosse, J. Henes, G. Grözinger, I. Kötter, P. Martirosian, F. Eibofner, F. Schick, M. Horger · 2015 · Journal of computer assisted tomography
48. What drives the comparative effectiveness of biologics vs. methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors.
    S. Kanters, E. Druyts, E. Mills, K. Thorlund · 2014 · Rheumatology
49. Investigational drugs for treating psoriatic arthritis
    B. Sheane, V. Chandran · 2014 · Expert Opinion on Investigational Drugs
50. Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment
    E. Keystone, A. Anisfeld, S. Ogale, J. Devenport, J. Curtis · 2014 · Journal of Rheumatology
51. Small molecular therapies for rheumatoid arthritis: where do we stand?
    S. Cohen · 2012 · Expert Opinion on Investigational Drugs
52. Infections associated with the use of biologic response modifiers in rheumatic diseases: a critical appraisal
    A. Malaviya, N. Haroon · 2011 · Indian Journal of Rheumatology
53. 70 – Clinical Features of Rheumatoid Arthritis
    S. Sweeney, E. D. Harris, G. Firestein · 2013 · Elsevier eBooks
54. Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
    L. Diep, Vincent Barbier, M. Doussière, Estelle Touboul, Claire Jesson, V. Deprez, J. Sobhy-Danial, P. Fardellone, V. Goëb · 2022 · Journal of Clinical Medicine
55. Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    S. Grimm, Ben F. M. Wijnen, R. Riemsma, D. Fayter, N. Armstrong, Charlotte Ahmadu, L. Brandts, K. Misso, J. Kirwan, J. Kleijnen et al. · 2021 · PharmacoEconomics (Auckland)
56. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis.
    Jesús Tornero Molina, Alejandro Balsa Criado, F. B. Blanco García, Ricardo Blanco Alonso, S. Bustabad, Jaime Calvo Alén, H. Corominas, Antonio Fernández Nebro, J. R. Román Ivorra, R. Sanmartí · 2020 · Reumatología Clínica
57. Most Appropriate Conventional Disease‐Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta‐Analysis
    G. Decarriere, T. Barnetche, B. Combe, C. Gaujoux-Viala, C. Lukas, J. Morel, C. Daien · 2020 · Arthritis care & research
58. Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817)
    T. Markatseli, A. Theodoridou, M. Zakalka, E. Koukli, E. Triantafyllidou, Sotiris Tsalavos, A. Andrianakos, A. Drosos · 2019 · Mediterranean Journal of Rheumatology
59. Use of synthetic and biologic DMARDs during pregnancy
    G. Balbi, V. Domingues, G. Balbi, G. D. de Jésus, R. Levy · 2019 · Expert Review of Clinical Immunology
60. Targeting IL-6: A review of data
    J. Smolen, D. Aletaha, E. Choy, Simon A. Jones, T. Takeuchi, I. Mcinnes · 2018 · Considerations in Medicine
61. Effects of a humanized anti-human IL-6 receptor monoclonal antibody on Nakajo-Nishimura syndrome
    F. Furukawa · 2018 · Trends in Immunotherapy
62. Dendrimers: Breaking the paradigm of current musculoskeletal autoimmune therapies
    D. Rodrigues, J. Oliveira, T. Santos, R. Reis · 2018 · Journal of Tissue Engineering and Regenerative Medicine
63. Are sample sizes of randomized clinical trials in rheumatoid arthritis too large?
    S. Çelik, Y. Yazici, H. Yazici · 2014 · European Journal of Clinical Investigation
64. Tocilizumab in Pediatric Rheumatology: The Clinical Experience
    R. Gurion, N. Singer · 2013 · Current Rheumatology Reports
65. [Tocilizumab in rheumatoid arthritis].
    J. Rueda-Gotor, Ricardo Blanco Alonso · 2011 · Reumatología Clínica
66. Princípios gerais do tratamento da artrite reumatoide inicial
    Licia Maria Henrique da Mota, Iêda Maria Magalhäes Laurindo, Leopoldo Luiz dos Santos · 2010
67. Tocilizumab for Painful Chronic Pancreatitis (TOPAC trial): Protocol for a phase 2 randomized, placebo-controlled, double-blind, investigator-initiated trial.
    Rasmus Hagn-Meincke, J. Frøkjær, A. Drewes, Charlotte Henneberg Holmboe, Klaus Krogh, R. B. Nedergaard, Line Davidsen, T. Okdahl, I. Haldorsen, Walter G. Park et al. · 2025 · Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
68. Dynamics of Modified Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis on the Background of 5-Year Therapy with an Interleukin 6 Receptor Inhibitor
    E. Gerasimova, T. Popkova, I. Kirillova, D. Gerasimova, E. Nasonov · 2024 · Doklady Biochemistry and Biophysics
69. Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report
    P. Kilić, Lucija Ikić, M. Mayer, M. Artuković, Ksenija Maštrović Radončić, Marina Ikić Matijašević · 2023 · Medicina
70. Perspective: repurposed Drugs for COVID-19
    Kesara Na‐Bangchang, Supattra Porasuphatana, Juntra Karbwang · 2022 · Archives of Medical Science
71. Tailoring biologic therapy for real-world rheumatoid arthritis patients
    C. Romano, S. Esposito, R. Ferrara, G. Cuomo · 2020 · Expert Opinion on Biological Therapy
72. Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease‐Modifying Antirheumatic Drugs
    Mariko Inoue, H. Kanda, Shoko Tateishi, K. Fujio · 2020 · Arthritis care & research
73. Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
    E. Mysler, M. Cardiel, R. Xavier, Alejandra López, A. Ramos-Esquivel · 2020 · Journal of clinical rheumatology
74. The Effect of Inhalant Organic Dust on Bone Health
    J. Carrington, J. Poole · 2018 · Current Allergy and Asthma Reports
75. Generalization and Extrapolation of Treatment Effects From Clinical Studies in Rheumatoid Arthritis
    S. Nair, W. Kievit, R. Janse, J. Bijlsma, J. Fransen, F. Lafeber, P. Welsing · 2014 · Arthritis care & research
76. Analysis of the Mechanism of Action of Biological Therapies in Monotherapy in Patients with Rheumatoid Arthritis: Beyond the ADACTA Study
    M. VictoriaHernndez, S. Vidal, R. Sanmartí · 2013 · Advances in Pharmacoepidemiology & Drug Safety
77. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab
    M. Fusama, H. Nakahara, Y. Hamano, Masayuki Nishide, K. Kawamoto, Takashi Hosokawa, S. Nozato, S. Higa, T. Igarashi, E. Takeuchi et al. · 2013
78. Improvement of health status evaluated by Arthritis Impact Measurement Scale 2 (AIMS-2) and Short Form-36 (SF-36) in patients with rheumatoid arthritis treated with tocilizumab
    M. Fusama, H. Nakahara, Y. Hamano, Masayuki Nishide, K. Kawamoto, Takashi Hosokawa, S. Nozato, S. Higa, T. Igarashi, E. Takeuchi et al. · 2013 · Modern Rheumatology
79. The Anemia of Inflammation
    B. Stein · 2012 · Journal of clinical rheumatology
80. Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial
    J. Pope, J. C. Thorne, B. Haraoui, E. Psaradellis, J. Sampalis · 2012 · Medical Science Monitor
81. Taking advances from bench to bedside during the last decade.
    M. Kok, P. Tak · 2012 · Baillière's Best Practice & Research : Clinical Rheumatology
82. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline
    S. Kawashiri, A. Kawakami, N. Iwamoto, K. Fujikawa, T. Aramaki, M. Tamai, S. Yamasaki, H. Nakamura, T. Origuchi, Y. Ueki et al. · 2011
83. Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy
    A. Russell, W. Olszynski, K. S. Davison, C. Koehn, B. Haraoui · 2010 · Clinical Rheumatology
84. [Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis].
    T. Popkova, D. Novikova, E. Nasonov · 2016 · Терапевтический архив
85. Beyond inflammation: metabolic implications of biological and TsDMARD therapies in dermatologic and rheumatologic diseases
    S. Corrao, S. Scibetta, N. Pardo, Ignazio Cangemi, Luigi Mirarchi, Giacomo Corrao, S. Amodeo, L. Calvo · 2026 · Frontiers in Immunology
86. scBlood: A comprehensive single-cell accessible chromatin database of blood cells
    Yu Zhao, Zheng-min Yu, Ting Cui, Li-Dong Li, Yan-Yu Li, Fengcui Qian, Li-wei Zhou, Ye Li, Qiao-li Fang, Xue Huang et al. · 2024 · Computational and Structural Biotechnology Journal
87. Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study
    G. Nagy, P. Géher, L. Tamási, E. Drescher, P. Keszthelyi, J. Pulai, L. Czirják, Z. Szekanecz, Gergely Kiss, L. Kovács · 2022 · Rheumatology Advances in Practice
88. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy
    C. Peterfy, J. Kremer, W. Rigby, N. Singer, C. Birchwood, D. Gill, W. Reiss, J. Pei, M. Michalska · 2020 · Journal of Rheumatology
89. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals
    O. Saiki, H. Uda · 2018 · Rheumatology International
90. [Macrophage activation syndrome secondary to tocilizumab: Myth or reality?].
    A. Deroux, F. Andry, L. Bouillet · 2016 · La Revue de medecine interne
91. Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts
    K. Tao, Hui Zeng, De-Ming Xiao, Ao Xiong, Jian Weng, Bin Kang · 2014 · Journal of Huazhong University of Science and Technology. Medical Sciences
92. Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunity.
    G. Pongratz, M. Fleck · 2012 · Current pharmaceutical design
93. Role of hepcidin in the development of anemia in patients with rheumatoid arthritis
    Elena Andreyevna Galushko, D A Belenky, Е Н Александрова, L N Kashnikova · 2012 · Rheumatology Science and Practice
94. БЫСТРЫЙ ЭФФЕКТ ТОЦИЛИЗУМАБА ПРИ РЕВМАТОИДНОМ АРТРИТЕ
    E. Panasyuk, V. N. Amirdzhanova, Aleksandrova En, E. Gubar, Galina Lukina, E. L. Luchikhina, E. Tsvetkova, T. Gavva, E. Fedorenko, A. S. Avdeyeva et al. · 2011 · RSP
95. In Vivo Fluorescence Imaging of E-Selectin: Quantitative Detection of Endothelial Activation in Arthritis
    L. Gompels · 2010
96. Translational strategies to implement personalized medicine: rheumatoid arthritis examples.
    B. Littman · 2009 · Personalized Medicine
97. Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab
    E. Feist, E. Nasonov · 2023 · Rheumatology
98. Antiinflammatory activity of natural dietary flavonoids
    Matheus Chiaradia de Souza, Ana Laura Tironi de Castilho, Carolina Mendes Tarran, Mateus Souza Zabeu, Leonardo de Liori Teixeira, A. Rozza · 2021 · Elsevier eBooks
99. Chapter 63 – Anti-cytokine Therapies
    Z. Tutuncu, A. Kavanaugh · 2017 · Elsevier eBooks
100. 57 – Acute Phase Reactants and the Concept of Inflammation
     A. Saxena, B. Cronstein · 2013 · Elsevier eBooks